Navigation Links
Targeting Metastatic Cancer From the Inside: Epeius Biotech Reveals a New Generation of Tools for Medical Gene Delivery
Date:10/6/2008

SAN MARINO, Calif., Oct. 6 /PRNewswire/ -- Epeius Biotechnologies Corporation today announced the publication of another landmark paper describing recent technological advances in medical gene delivery. The latest scientific paper, entitled "Targeting metastatic cancer from the inside: A new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ," was published in the October issue of the International Journal of Oncology (IJO). The paper describes the new state-of-the-art in tumor-targeting biotechnology, nanotechnology, and therapeutic gene delivery developed for clinical applications in the field of oncology. The paper lays the scientific, preclinical and clinical foundations for new applications of personalized medicine, specifically for patients with metastatic cancer.

Based on recent breakthroughs in pathotropic (or disease-seeking) tumor targeting technologies, a new generation of anti-cancer agents is currently being developed. Anti-cancer agents such as Rexin-G can be delivered by simple intravenous infusion, yet are designed to seek out and accumulate in primary and metastatic lesions that have spread throughout the body. Rexin-G is essentially a pathotropically targeted nanoparticle of genetic medicine that is guided by a proprietary targeting technology and is designed to deliver a killer-gene selectively to tumor cells and their associated (proliferative) blood supply. Representing the first and so far only targeted genetic medicine proven to be both safe and effective in the clinic, Rexin-G is commercially available in the Philippines -- for use in all solid tumors that are refractory to standard chemotherapy -- and is currently in clinical trials in the USA for several cancer indications.

Following the validation of its lead product in the clinic, Epeius Biotech has developed a second tumor-targeted anti-cancer agent, named Reximmune-C, designed to work in concert with Rexin-G by providing a l
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vascular Biogenics Ltd. Presented With the Frost & Sullivan 2008 European Gene Expression Targeting Platform Technology Innovation Award
2. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
3. MicuRx Pharmaceuticals Selects Next-Generation Antibiotic Candidate Targeting MRSA and Expands Operation in China
4. Realtime Achieves ISO 13485:2003 Certification Targeting BioTech Quality Initiative
5. New Study Raises Questions About Prostate Cancer Therapies Targeting Insulin-Like Growth Factor Receptor
6. Novel Approach to Treat Alzheimers and Other Diseases Offered by Targeting Cell Membrane RAFTS
7. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
8. Cardiums Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion
9. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
10. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
11. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... MN (PRWEB) , ... July 31, 2015 , ... Ralco ... Enrichment Center at the Lyon County Fair to be held August 5-9 in Marshall. ... about where their meals come from and how agriculture impacts their daily lives. This ...
(Date:7/30/2015)... July 30, 2015 According to ... (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, ... Preclinical, Clinical Trial), by End Users - Global Forecast ... expected to reach USD 2,107.99 million by 2020 from ... 15.29%. Browse more than ...
(Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
(Date:7/29/2015)... July 30, 2015 Sanofi, ... for the second quarter of 2015. CEO ... and its performance in different businesses. ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Topics covered in ... - Performance drivers - ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Biosimulation Market Worth 2,107.99 Million USD by 2020 2Biosimulation Market Worth 2,107.99 Million USD by 2020 3Biosimulation Market Worth 2,107.99 Million USD by 2020 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... a privately-held company focused on advancing women,s reproductive health, today ... A financing, bringing the total funding to $20 million. The ... the round include Kleiner Perkins Caufield and Byers, TPG Biotech ... the last year, we have executed an aggressive operating plan ...
... 2012   Reportlinker.com announces that a new market ... U.S. Tissue Engineering Markets ... The scope of this research service primarily ... the wound care and surgery space. Surgery ...
... Feb. 1, 2012 Sangamo BioSciences, Inc. (Nasdaq: ... fourth quarter and full year 2011 financial results on Wednesday, ... will be followed by a conference call at 5:00 p.m. ... and webcast. During the conference call, the company will review ...
Cached Biology Technology:Auxogyn Completes $20 Million In Series A Funding 2Auxogyn Completes $20 Million In Series A Funding 3U.S. Tissue Engineering Markets 2U.S. Tissue Engineering Markets 3Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast 2
(Date:7/31/2015)... , Kina, 31. juli 2015 Den 10. ... afholdt af BGI fra den 22. - 25. oktober i ... Konferencen fejrer sin 10-års fødselsdag i år. Siden starten ... indflydelsesrige årlige møder på ,omik,-feltet, og er en af ... ICG-10 fokuserer på nylige gennembrud og fremskridt ...
(Date:7/31/2015)... julio de 2015 BGI llevará a cabo la ... 22 al 25 de octubre de 2015, en ... celebra su décimo aniversario este año. Desde su inauguración ... las reuniones anuales más influyentes del mundo en los ... conferencias científicas más dinámicas, entusiastas y amenas. ...
(Date:7/31/2015)... , 31 de julho de 2015 ... www.icg-10.org ) será realizada pela BGI de 22-25 de ... . A conferência está celebrando seu 10 ... 2006, a ICG se tornou uma das reuniões mais ... dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... a new way of looking beneath the ocean surface ... shrinking. , A remote sensor system developed by Associate ... at MIT, Northeastern University and the Naval Research Laboratory, ... as well as small schools, over a 10,000-square-kilometer area ...
... of Pennsylvania, demonstrate that biodegradable nano-particles containing two ... breast tumors. The unique properties of the ... to deliver two distinct drugs, paclitaxel, the leading ... Taxol, and doxorubicin directly to tumors implanted in ...
... have found a way to keep a protein "watchdog" on ... - if they can keep it on a leash of ... team of scientists including Purdue University's Susan M. Mendrysa has ... has the ability to halt the progression of intestinal tumors ...
Cached Biology News:One fish, two fish: New MIT sensor improves fish counts 2Nano-particles effective in killing cancer with one-two punch of chemotherapeutics 2Loosen leash on cancer protein 'watchdog,' researchers say 2Loosen leash on cancer protein 'watchdog,' researchers say 3Loosen leash on cancer protein 'watchdog,' researchers say 4
IEX-1 S/L (H-20)...
Mouse monoclonal [1.T.4] to WAVE 1 ( Abpromise for all tested applications). Antigen: His6 fusion protein corresponding to full-length rat WAVE1. Entrez Gene ID: 8936...
For the differentiation of mouse embryonic stem cells tooligodendrocytes....
VAP-1 (S-13)...
Biology Products: